Browse the evidence

GLP-1 receptor agonists significantly improve lipid profiles (reducing Total Cholesterol and LDL-C, increasing HDL-C) and fasting plasma glucose in obese individuals with psychotic disorders, but do not significantly affect waist circumference, systolic/diastolic blood pressure, or triglycerides.

GLP-1 receptor agonists improve blood sugar and cholesterol levels (lowering bad cholesterol and triglycerides, raising good cholesterol) in patients with psychotic disorders, but they do not significantly lower blood pressure or waist circumference. This makes them valuable for metabolic health, even if blood pressure remains unchanged.

Meeting multiple glycemic criteria (IFG, IGT, and/or elevated HbA1c) for prediabetes significantly increases the risk of progressing to type 2 diabetes compared to meeting only one criterion.

If you have prediabetes, ask your doctor to check all three glycemic markers (fasting glucose, 2-hour post-meal glucose, and HbA1c). Meeting more than one abnormal result means your risk of developing type 2 diabetes is much higher, and you should prioritize intensive lifestyle changes or discuss medication with your provider immediately.

Obesity is a heterogeneous condition where distinct subtypes exist based on metabolic and genetic profiles, necessitating personalized treatment strategies rather than uniform BMI-based approaches.

Stop treating all obesity as the same. Your doctor should look beyond your weight to your metabolic health (blood sugar, lipids) and genetics to determine the best treatment for you, which might include specific medications or lifestyle changes tailored to your body's unique biology.

Storing fat subcutaneously (especially in the hips and thighs) is metabolically favorable compared to storing it viscerally or in the liver, reducing the risk of type 2 diabetes and cardiovascular disease despite higher overall body fat.

Focus on maintaining muscle mass and healthy fat distribution rather than just losing weight. If you have a 'pear' shape (fat stored in hips/thighs), you may have a lower risk of diabetes than someone with a 'apple' shape (visceral fat), even if your BMI is high.

Sarcopenia (defined by low handgrip strength and/or low muscle mass) is associated with a significantly higher long-term risk of developing atrial fibrillation (AF) in Caucasian populations, independent of genetic predisposition and lifestyle factors.

Prioritize resistance training and adequate protein intake to maintain muscle mass and strength, especially if you are female or under 65, as these groups showed a stronger link between muscle loss and heart rhythm issues. Regular assessment of handgrip strength and muscle mass can serve as an early warning system for cardiovascular risk.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior glycemic control and greater weight loss compared to GLP-1 receptor agonists (semaglutide, dulaglutide) and insulin analogs (degludec, glargine) in patients with type 2 diabetes.

If you have Type 2 Diabetes or obesity, Tirzepatide is a once-weekly injection that lowers blood sugar and reduces body weight more effectively than current GLP-1 drugs (like semaglutide) or insulin. It works by mimicking two gut hormones (GIP and GLP-1). Common side effects are gastrointestinal, but they often decrease over time. Consult a doctor to see if you are a candidate.

Semaglutide 2.4 mg treatment leads to preferential loss of fat mass over lean body mass, which supports improvements in physical function and walking capacity.

Semaglutide 2.4 mg helps you lose fat mass more than lean body mass, which supports your physical function and walking capacity. This is achieved through once-weekly injections combined with lifestyle changes.

Current GLP-1-based anti-obesity medications (AOMs) achieve profound acute body weight loss (up to 25%) but are associated with significant real-world treatment discontinuation (up to 50%) due to gastrointestinal side effects and lack of lifestyle counseling, necessitating novel formulations with improved tolerability.

While GLP-1 drugs like semaglutide and tirzepatide produce significant weight loss, real-world adherence is a major hurdle due to gastrointestinal side effects. To maximize success, patients should utilize flexible, patient-determined titration schedules rather than fixed rapid escalation, and consider prophylactic anti-emetics if needed, as these strategies improve long-term tolerability and adherence.

Bariatric surgery (RYGB, SG, BPD/DS) is the most effective long-term treatment for severe obesity, achieving 15-30% total weight loss, but carries significant risks of micronutrient deficiencies and lean body mass loss due to anatomical malabsorption.

Bariatric surgery is the most effective long-term weight loss option for severe obesity, but it is not a simple fix. It requires lifelong commitment to high-dose nutritional supplementation and regular medical monitoring to prevent serious deficiencies in iron, B12, and calcium, as well as loss of muscle mass. The procedure works through complex metabolic changes, not just stomach size reduction.

Bariatric surgery significantly increases the risk of bone loss and fractures, particularly in malabsorptive procedures, due to reduced calcium absorption and secondary hyperparathyroidism, which is not fully mitigated by standard calcium and vitamin D supplementation.

If you have bariatric surgery, especially a malabsorptive type like gastric bypass, your risk of bone fractures increases significantly. Standard calcium and vitamin D supplements often fail to prevent this bone loss. You need specialized, long-term bone health monitoring beyond standard care.

Anti-obesity medications (AOMs) such as GLP-1 receptor agonists do not render lifestyle-based treatments obsolete; rather, they act synergistically by addressing physiological barriers to weight loss, allowing behavioral interventions to focus on optimizing body composition and long-term health maintenance.

Do not stop your lifestyle efforts when starting medication. Use the medication to manage hunger and physiological resistance, then redirect that energy into building fitness, muscle mass, and healthy eating habits. The medication handles the biology; you handle the lifestyle optimization for long-term health.

A ketogenic diet tends to cause greater losses in body weight, fat mass, and fat-free mass compared to higher-carbohydrate diets, likely due to differences in calorie and protein intake and fluid shifts rather than the diet itself being inherently superior for fat loss.

If you want to lose fat, a ketogenic diet can help you lose weight, but it is not inherently better than other diets. The greater weight loss seen is likely due to eating fewer calories and losing water weight. Ensure you are consuming enough protein to preserve muscle mass, regardless of the diet you choose.

A ketogenic diet has similar effects on maximal strength or strength gains from resistance training compared to a higher-carbohydrate diet, although a minority of studies show superior effects for non-ketogenic diets.

If your goal is to build strength, you can do so on a ketogenic diet. Studies show similar strength gains compared to high-carbohydrate diets. However, some studies suggest non-ketogenic diets might be slightly superior, so monitor your progress and adjust if needed.

Gut microbiota composition determines individual variability in postprandial glycemic responses to standardized meals, enabling prediction of glucose spikes via machine learning models trained on metagenomic data.

Your gut bacteria uniquely determine how your blood sugar reacts to food. This is why one person might spike after a meal while another doesn't. Personalized nutrition strategies based on your microbiome can help manage glucose levels more effectively than generic advice.

Increased circulating levels of branched-chain amino acids (BCAAs) and imidazole propionate, linked to gut microbiota function, are associated with insulin resistance and higher risk of type 2 diabetes.

High levels of certain metabolites like BCAAs and imidazole propionate in your blood are linked to insulin resistance. These are partly produced by your gut bacteria, suggesting that a balanced diet supporting a healthy microbiome is important for metabolic health.

Newer GLP-1RAs achieve average weight loss of 15% or greater, but a substantial number of patients fail to achieve even 5% weight loss, and weight loss is lower in older adults, males, and those with type 2 diabetes.

If you are on a GLP-1RA and not losing weight, you are not alone. Older adults, men, and those with type 2 diabetes often lose less weight on average. Discuss this with your doctor to see if lifestyle adjustments or other strategies can help improve your response.

Obesity and metabolic syndrome significantly impair the anabolic response (lean mass and strength gains) to resistance exercise and protein supplementation in older adults, creating anabolic resistance that limits muscle recovery during weight management.

If you are older and have excess body fat or metabolic issues, standard resistance training and protein intake will be less effective at building muscle than they are for leaner individuals. This is due to 'anabolic resistance' caused by inflammation and insulin resistance. To overcome this, you likely need higher-quality protein sources (like whey/casein blends with creatine and omega-3s) rather than just any protein, and you must prioritize metabolic health improvements alongside training.

Higher doses of tirzepatide (10-15 mg), younger age, and female sex are associated with a longer time to reach a weight plateau compared to lower doses (5 mg), older age, and male sex.

If you are on tirzepatide and your weight loss slows down significantly (plateau), do not panic or assume the drug has stopped working. This is a normal physiological adaptation. The study shows that people on higher doses, younger people, and women tend to reach this plateau later because they lose more total weight. Focus on maintaining the negative energy balance rather than chasing rapid scale changes. If you are on a lower dose (5mg), you may plateau sooner than those on 10-15mg, but this does not mean the treatment is ineffective.

The efficacy of GLP-1RA combined with lifestyle modification is influenced by treatment duration, drug type (semaglutide/tirzepatide), dosing frequency (weekly), and geographic region (North America).

For the best weight loss results with GLP-1RAs, choose a weekly formulation (like semaglutide or tirzepatide) if possible, maintain the treatment for at least a year, and ensure your lifestyle intervention is consistent. Regional factors may also play a role in outcomes.

Discontinuation rates for weight-reducing (WR) diabetes-specific medications are nearly twice as high as those for weight-inducing (WI) medications, indicating poor persistence with preferred therapies.

If you start a weight-reducing diabetes medication, be prepared for a higher chance of stopping it compared to older weight-gain drugs. This is common, so don't be discouraged. Talk to your doctor about managing side effects, starting with a lower dose, or switching to an oral formulation if injections are the issue. Persistence is key to seeing long-term benefits.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce hepatic steatosis and improve metabolic markers in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), but they do not significantly improve liver fibrosis.

GLP-1 medications like semaglutide and tirzepatide are effective at reducing liver fat and improving metabolic health in people with fatty liver disease. However, they do not currently appear to reverse liver scarring (fibrosis). While they offer significant benefits for steatosis and weight loss, patients should be aware of common gastrointestinal side effects and the current limitation regarding fibrosis reversal.

Dual or Triple Receptor Agonists (combining GLP-1, GIP, and/or Glucagon) offer superior reduction in liver fat and weight loss compared to selective GLP-1 receptor agonists alone.

Newer 'dual' and 'triple' hormone medications (like Tirzepatide or Efinopegdutide) appear to reduce liver fat and weight more effectively than older GLP-1 drugs alone. These are currently under investigation and may become the preferred treatment for MASLD, especially for those who need significant weight loss and liver fat reduction.

Gastrointestinal adverse events (nausea, vomiting, diarrhea, dyspepsia) associated with tirzepatide contribute minimally (up to 3.1%) to total weight reduction, with weight loss occurring similarly in patients with and without these symptoms.

Do not expect nausea or vomiting to drive your weight loss. Clinical data shows that patients who experience no gastrointestinal side effects lose just as much weight as those who do. Focus on the hormonal mechanism of the drug rather than tolerating discomfort as a sign of efficacy.

Fish oil supplementation (3.85 g/day EPA+DHA) combined with resistance training significantly increases absolute and relative upper-body strength and relative lower-body strength in young adults compared to placebo, without significantly altering lean body mass.

If you are a young, healthy adult doing resistance training 3 times a week, adding 3.85 grams of combined EPA and DHA daily (from fish oil) can help you get stronger, especially in your upper body and relative strength, without necessarily making you bigger. This effect is likely due to improved muscle quality and neural factors, not just muscle growth. Ensure you are getting enough protein (at least 1.2g/kg/day) as this may be required for the fish oil to work effectively.